Trial Profile
Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 08 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2014 to 1 Mar 2014.
- 12 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.